DNA-DIAGNOSTIC

Time is short

The list is not

del1(p32) (STIL-TAL1)
t(1;11) (p32;q23) (MLL-EPS15)
t(1;11) (q21;q23) (MLL-MLLT11)
t(1;19) (q23;p13) (TCF3-PBX1)
t(3;5) (q25;q34) (NPM1-MLF1)
t(3;21) (q26;q22) (RUNX1-MDS1/EVI1)
t(4;11) (q21;q23) (MLL-AFF1)
t(5;12) (q33;p13) (ETV6-PDGFRB)
t(5;17) (q35;q21) (NPM1-RARA)
t(6;9) (p23;q34) (DEK-NUP214)
t(6;11) (q27;q23) (MLL-MLLT4)
t(8;21) (q22;q22) (RUNX1-RUNX1T1)
t(9;9) (q34;q34) (SET-NUP214)
t(9;11) (p22;q23) (MLL-MLLT3)
t(9;12) (q34;p13) (ETV6-ABL1)
t(9,22) (q34;q11) (BCR-ABL1)
t(10;11) (p12;q23) (MLL-MLLT10)
t(11;17) (q23;q21) (MLL-MLLT6)
t(11;17) (q23;q21) (ZBTB16-RARA)
t(11;19) (q23;p13.1) (MLL-ELL)
t(11;19) (q23;p13.3) (MLL-MLLT1)
t(12;21) (p13;q22) (ETV6-RUNX1)
t(12;22) p13;q11) (ETV6-MN1)
t(15;17) (q24;q21) (PML-RARA)
inv(16) (p13;q22) (CBFB-MYH11)
t(16;21) (p11;q22) (FUS-ERG)
t(17;19) (q22;p13) (TCF3-HLF)
t(X;11) (q13;q23) (MLL-FOXO4)

Run a
HemaVision®-28N
28 Translocations
145+ Breakpoints
In just 12 hours
CE IVD

Screening for 28 Leukemia Associated Translocations

HemaVision®-28N, Cat. No. HV01-28N

- Screening test for AML, ALL and CML
- Detection of 28 translocations
- Detection of +145 breakpoints and splice variants
- In just 12 hours
- Use standard PCR instrument and lab equipments
- CE marked for IVD
- 25 tests per kit

Total RNA from Blood or Bone Marrow

cDNA synthesis

Master PCR reactions M1-8



Split-out PCR reactions M6A-E



Interpretation:

M6 and M6B are positive (397 bp). Patient has a translocation at t(9;22)(q34;q11) with a breakpoint in the M-bcr (Major breakpoint cluster region) at position BCRex13-ABL1ex2 (b2a2) generating a P210 (kDa) fusion protein.

1. PURPOSE OF THE TEST

HemaVision®-28N is a multiplex RT-PCR based assay (Reverse Transcription of RNA followed by PCR and agarose gel electrophoresis) for detection of leukemia associated fusion gene transcripts in total RNA from whole blood or bone marrow samples. HemaVision®-28N is a 12 hour CE IVD marked in vitro diagnostic test for qualitative screening of 28 chromosome translocations involved in chronic and acute leukemia. The test allows professionals to react rapid and with precision in terms of treatment planning, while profiting from the cost- and labour-effective screening process.

HemaVision®-28N provides a rapid screen for 28 translocations with more than 145 clinically relevant chromosomal breakpoints. Translocation breakpoints and alternative splice variants are detected.

The test requires a thermal cycler and standard laboratory equipment. It can be completed in 12 hours after RNA extraction.

HemaVision®-28N detects the 28 translocations, see below. HemaVision®-28N also gives information about the exons located at the breakpoint and presence of splice variants.

del1(p32) (STIL-TAL1)
t(1;11) (p32;q23) (MLL-EPS15)
t(1;11) (q21;q23) (MLL-MLLT11)
t(1;19) (q23;p13) (TCF3-PBX1)
t(3;5) (q25;q34) (NPM1-MLF1)
t(3;21) (q26;q22) (RUNX1-MDS1/EVI1)
t(4;11) (q21;q23) (MLL-AFF1)
t(5;12) (q33;p13) (ETV6-PDGFRB)
t(5;17) (q35;q21) (NPM1-RARA)
t(6;9) (p23;q34) (DEK-NUP214)
t(6;11) (q27;q23) (MLL-MLLT4)
t(8;21) (q22;q22) (RUNX1-RUNX1T1)
t(9;9) (q34;q34) (SET-NUP214)
t(9;11) (p22;q23) (MLL-MLLT3)
t(9;12) (q34;p13) (ETV6-ABL1)
t(9,22) (q34;q11) (BCR-ABL1)
t(10;11) (p12;q23) (MLL-MLLT10)
t(11;17) (q23;q21) (MLL-MLLT6)
t(11;17) (q23;q21) (ZBTB16-RARA)
t(11;19) (q23;p13.1) (MLL-ELL)
t(11;19) (q23;p13.3) (MLL-MLLT1)
t(12;21) (p13;q22) (ETV6-RUNX1)
t(12;22) (p13;q11) (ETV6-MN1)
t(15;17) (q24;q21) (PML-RARA)
inv(16) (p13;q22) (CBFB-MYH11)
t(16;21) (p11;q22) (FUS-ERG)
t(17;19) (q22;p13) (TCF3-HLF)
t(X;11) (q13;q23) (MLL-FOXO4)

DNA-DIAGNOSTIC

Run a
HemaVision®-28N

Availability / questions
Our team and distributors are always at hand to answer all your questions.
Contact us to find your nearest HemaVision® partner.

For more information, contact
DNA Diagnostic A/S
Voldbjergvej 16
8240 Risskov
Denmark

Tel. +45 87 32 30 50
Fax +45 87 32 30 59
info@dna-diagnostic.com
www.dna-diagnostic.com

DNA Diagnostic A/S (previously named DNA Technology A/S) was established in 1992. DNA Diagnostic A/S is an ISO 13485 certified developer, manufacturer, and worldwide supplier of PCR based CE IVD marked in vitro diagnostic kits.